Strattera is used to treat attention deficit hyperactivity disorder (ADHD) in children and adults who are exposed to certain substances such as amphetamine, dextroamphetamine, and other non-stimulants. Strattera may also be used for the treatment of ADHD in adults with a history of substance abuse, including amphetamine, dextroamphetamine, and other non-stimulants.

Your doctor may start you on Strattera and gradually increase your dose until you are 100 percent controlled. If you are in a position where you cannot take Strattera slowly, you may need to increase your dose as slowly as you can before continuing to take it. Do not take more or less than the recommended dose. If you are not sure whether you are taking Strattera, talk to your doctor. If you are taking Strattera more than the recommended dose, call your doctor.

Tell your doctor if your dosage is more than the recommended dose. You may not be able to take Strattera. Strattera may be taken with or without food. Your doctor may increase your dose if you become more sensitive to your food or drink. If you become sensitive to food or drink while taking Strattera, call your doctor immediately. Strattera may cause sleepiness and drowsiness. If you feel drowsy or have trouble falling asleep, try getting up slowly. Do not stop your medication abruptly. Your doctor may gradually lower your dose.

Tell your doctor if your dosage is not consistent with the recommended dose.

If you have not taken your Strattera regularly at the recommended dose, your dosage may be increased to make up for the missed dose. If you are not sure, ask your doctor for help. Continue taking your Strattera even if you think well.

If you are taking Strattera and have not taken your usual dose, your doctor may increase your dose as slowly as possible. This may reduce your chance of getting a side effect. If you are not sure, talk to your doctor.

Tell your doctor if you are taking Strattera in combination with another substance.

Tell your doctor if you are taking Strattera in combination with alcohol, especially when drinking alcohol.

If you are taking Strattera and you are not sure whether you are taking it correctly, talk to your doctor.

Stopping Strattera suddenly may cause a sudden and severe decrease in your alertness or coordination.

Your doctor may stop your treatment and ask you to stop taking Strattera. Do not stop taking Strattera suddenly.

Do not give your Strattera to anyone else. Do not treat someone else as Strattera can cause drowsiness and other side effects.

Do not take Strattera with anything other than a full glass of water.

Tell your doctor if you have ever had difficulty controlling your sleep. Your doctor may have told you not to drink alcohol while taking Strattera. Alcohol may make Strattera less effective and increase drowsiness.

If you are being treated for ADHD, your doctor may order some tests to measure your blood sugar before you start taking Strattera. You should tell your doctor before starting treatment that you are taking Strattera. Your doctor will tell you if your blood sugar test is normal before your Strattera treatment.

If you are being treated for ADHD and have not yet finished the treatment, your doctor may order some tests to measure your blood sugar before you start taking Strattera.

If you are being treated for ADHD and your blood sugar test is negative, your doctor will order some tests to measure your blood sugar before you start taking Strattera.

Do not give your Strattera to someone else.

Tell your doctor if you are taking Strattera in combination with alcohol.

If you have any questions about how to take Strattera, talk to your doctor.

If you are taking Strattera and your doctor has prescribed it, tell your doctor. Strattera is not usually taken with alcohol. But some people have had side effects from taking Strattera.

Strattera 50mg (20mg)is a non-stimulant medication used to treat attention-deficit hyperactivity disorder (ADHD) in children and adults. It contains the active ingredient atomoxetine, which belongs to the class of atomoxetine drugs, and is available only with a doctor’s prescription.

The main side effects include dizziness, drowsiness, and dry mouth. More serious side effects may be possible, but should be discussed with a doctor. If any of these become troublesome or last, they are unlikely to be worth the risk. However, if they persist or become troublesome, they should be treated with non-drug methods and with non-stimulant medicines.

Before starting treatment with Strattera, it is important to tell your doctor if you have any medical conditions, are taking other medicines, are allergic to any component of the drug, have kidney or heart problems, are pregnant or breast-feeding, if you are already taking medication, or are breastfeeding. Your doctor should also know if you have any problems with your liver or you have liver or kidney problems. You should also know that Strattera may cause constipation. Swallow the tablets with a glass of water.

Tell your doctor if you are taking any other medicines, including any that you get from your pharmacy, including herbal supplements. You should also know that any other medicines you take, including recreational or herbal medicines, should be carefully checked. Your doctor will probably start treatment with Strattera several weeks before your IQ test results will be stable. You should also know that treatment with Strattera will help you remember to take it when you have next symptoms. This is for your safety. You should also know that treatment with Strattera may worsen some symptoms of ADHD.

Show MoreTreatment with Strattera may help you feel better

The most common side effects of atomoxetine include drowsiness, dry mouth, insomnia, restlessness, agitation, restlessness, restlessness, tremor, drowsiness, increased appetite, nausea, vomiting, and headache. If these effects persist or worsen, contact your doctor.

The most common side effects of Strattera include drowsiness, restlessness, dry mouth, insomnia, restlessness, fatigue, restlessness, excitability, confusion, difficulty following movements, problems with memory, and difficulty concentrating and shaking.

Do not take Strattera:

• if you have a hypersensitivity to any of the ingredients listed at the end of the CMI.
• in combination with a medicine known as a selective norepinephrine reuptake inhibitor (SNRI).
• on the basis of a clinical study demonstrating an increased risk of cardiovascular events in ADHD treated with Strattera compared with placebo, in children and adolescents, who had normal IQ, and who had a normal IQ score.

Tell your doctor if you have any other medical conditions, including if you have problems with your liver or you are taking any other medicines.

The most common side effects of atomoxetine include drowsiness, dry mouth, insomnia, restlessness, fatigue, restlessness, excitability, confusion, difficulty following movements, and headache.

The most common side effects of Strattera may include nausea, dry mouth, insomnia, restlessness, and tremor. If these effects worsen, or you develop other side effects, contact your doctor.

Strattera is not recommended for use in children or adolescents under the age of 18.

Show MoreStrattera (atomoxetine) is a selective norepinephrine reuptake inhibitor (SNRI) which has been used for a long time. It is indicated for the treatment of ADHD in children and adolescents under the age of 18.

The most common side effects of Strattera may include drowsiness, dry mouth, insomnia, restlessness, nausea, vomiting, and headache.

The most common side effects of Strattera may include drowsiness, dizziness, abnormal dreams, difficulty in concentrating, and nausea. Contact your doctor at once if these effects persist or worsen.

ADHD Medication For Children

Children with ADHD: A Detailed Guide

ADHD is a common neurodevelopmental disorder (NDD) that affects children, affecting the brain chemistry, mood, and behavior. Symptoms include trouble sleeping, irritability, and changes in behavior. ADHD often goes unnoticed and has no known cause. In this article, we will delve into the various aspects of ADHD and share the best ADHD treatment options for children. This includes various medications, such as ADHD medications, and strategies to manage symptoms effectively. Understanding the different treatment options is crucial for children who struggle with ADHD symptoms. This information can help children to make informed decisions about their ADHD treatment. Common ADHD treatments include:

Adderall: A Medication for Attention-deficit Hyperactivity Disorder (ADHD)

Adderall (Atomoxetine) is a prescription medication for ADHD that has been shown to be effective for children with this condition. It belongs to a class of medications called selective norepinephrine reuptake inhibitors (SNRIs). It works by increasing levels of norepinephrine in the brain, which helps to slow down and even stop certain behaviors like repetitive behaviors. This medication is commonly used in adults and children who have ADHD, as well as in children who do not, or are unsure about their symptoms. Adderall is available in several forms, including oral tablets, injections, and patches, which can be used to treat various symptoms. It is important to follow the dosage and usage instructions provided by your healthcare provider to ensure you get the best possible treatment for your child. It is also important to consult with a healthcare professional to determine if Adderall is right for you.

Objective:To compare the efficacy of the combination of atomoxetine, Strattera and duloxetine in the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. Design: a 6-week, open-label, flexible-dose, randomized, fixed-dose, flexible-dose, parallel-group, parallel-group, fixed-dose, flexible-dose study. Participants: 18 to 80 patients with ADHD, 18 to 80 patients with narcolepsy, and 18 to 80 patients with ADHD. Study site: Canada; Health Canada (HCP Canada) and the US Food and Drug Administration (FDA). Primary efficacy outcome measures: symptom reduction and/or total daily dose of atomoxetine and duloxetine versus placebo. Secondary efficacy measures: symptom reduction and/or total daily dose of atomoxetine and duloxetine versus placebo. Safety outcome measures: improvement in the primary outcome measure, symptom reduction and/or total daily dose of atomoxetine and duloxetine versus placebo. Safety and tolerability outcomes: improvement in the secondary outcome measures, symptom reduction and/or total daily dose of atomoxetine and duloxetine versus placebo. Data source: Clinical Trials Experience (CTs) database, Health Canada, Canada. Aims: The primary efficacy outcome measures in the flexible-dose, open-label, fixed-dose, flexible-dose, open-label, parallel-group, fixed-dose, flexible-dose, open-label, fixed-dose, flexible-dose, and open-label clinical trial were the Global Severity of Illness (GSI) scale, the Short-Form 36 (SF-36), and the Clinical Global Imatitude Domain-36 (CGI-36). Secondary outcomes measures: symptom reduction and/or total daily dose of atomoxetine versus placebo. Safety outcome measures: improvement in the primary outcome measure, symptom reduction and/or total daily dose of atomoxetine versus placebo. Safety and tolerability outcomes: improvement in the secondary outcome measures, symptom reduction and/or total daily dose of atomoxetine versus placebo. A total of 2,739 patients completed the study. Patients were randomized (1:1) to the following groups: (a) the standard of care (STC), (b) the combination of atomoxetine and duloxetine, (c) the combination of atomoxetine and duloxetine, (d) the combination of atomoxetine and duloxetine, and (e) the combination of atomoxetine and duloxetine and placebo. Patients who completed the study had to have their primary outcome measure evaluated at least six months prior to randomization.

METHODS: Participants were randomized to the treatment arms (atomoxetine, Strattera, and duloxetine) or not. The primary outcome measure was total daily dose of atomoxetine (Strattera vs placebo) and duloxetine (Strattera vs placebo). Secondary outcomes were the Global Severity of Illness (GSI) scale, the SF-36, and the Clinical Global Imatitude Domain-36. All other secondary outcomes were assessed using the same scales as in the primary outcome measures, but at the discretion of the primary outcome measure. Patients were excluded if they had a known allergy to atomoxetine (hypersensitivity to atomoxetine, history of allergy, or history of allergy to duloxetine) or if they were taking duloxetine (duloxetine vs placebo) or were currently taking atomoxetine. Patients with a history of allergy to atomoxetine were also excluded. A total of 1,749 patients were screened for inclusion. The study population was screened for all patients who had a positive diagnosis of ADHD or narcolepsy at baseline. The study population was also screened for patients who had a positive diagnosis of ADHD or narcolepsy at baseline, and a negative diagnosis of ADHD or narcolepsy. Patients who were not at baseline or who had a positive diagnosis of ADHD or narcolepsy were excluded. All patients were enrolled in a random-number sequence using the same study protocol as in the primary outcome measure. All patients were randomized to the treatment arms, and the treatment arms were also assigned a treatment dose of atomoxetine (Strattera and duloxetine) or duloxetine (Strattera and duloxetine). The treatment groups were similar in terms of baseline characteristics. The primary endpoints were change in the Global Severity of Illness scale, the SF-36, and the Clinical Global Imatitude Domain-36.